PharmaCyte Biotech, Inc.

Common Stock SEC Reporting - Current
Verified Company Profile 8/30/2017
Contact Info
  • 23046 Avenida de la Carlota
  • Suite 600
  • Laguna Hills, CA 92653

Business Description

Financial Reporting/Disclosure
Reporting Status U.S. Reporting: SEC Reporting
Audited Financials Audited
Latest Report Jul 31, 2017 10-Q
CIK 0001157075
Fiscal Year End 4/30
OTC Marketplace OTCQB
Profile Data
SIC - Industry Classification 2833 - Medicinal and botanicals
Incorporated In: NV, USA
Year of Inc. 1996
Employees 10 a/o Feb 17, 2017
Company Officers/Contacts
Kenneth L. Waggoner, JD CEO, President, General Counsel
Gerald W. Crabtree, PhD COO
Carlos A. Trujillo CFO
Company Directors
Kenneth L. Waggoner, JD Chairman
Thomas Liquard Independent Director, Audit Committee Member, Compensation Committee Member
Michael M. Abecassis, MD Independent Director, Nominating Committee Member
Gerald W. Crabtree, PhD Compensation Committee Member
Raymond C.F. Tong Audit Committee Member
Carlos A. Trujillo
Thomas C.K. Yuen Independent Director, Compensation Committee Member
Service Providers
Investment Bank
Chardan Capital Markets
17 State Street
Suite 1600
New York, NY, 10004
United States
Accounting/Auditing Firm
Armanino LLP
12657 Alcosta Blvd
Suite 500
San Ramon, CA, 94583
United States
Securities Counsel
Pepper Hamilton LLP
New York Times Building
620 Eighth Avenue/37th Floor
New York, NY, 10018-1405
United States
Investor Relations Firm
Company History
  • Formerly=Nuvilex, Inc. until 1-2015
  •, Inc. until 3-2009
PMCB Security Details
Share Structure
Market Value1 $55,129,956 a/o Oct 20, 2017
Authorized Shares 1,490,000,000 a/o Aug 03, 2017
Outstanding Shares 973,167,811 a/o Aug 03, 2017
-Restricted Not Available
-Unrestricted Not Available
Held at DTC Not Available
Float 935,967,811 a/o Aug 03, 2017
Par Value 0.0001
Shareholders of Record 1,300 a/o Aug 03, 2017
Short Selling Data
Short Interest 14,000 (-82.68%)
Sep 29, 2017
Significant Failures to Deliver No

1Market Value calculated only for respective security